DRR168583
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.580
- FATTY_ACID_METABOLISM+0.430
- ADIPOGENESIS+0.400
- XENOBIOTIC_METABOLISM+0.330
- PEROXISOME+0.320
- PROTEIN_SECRETION+0.320
- KRAS_SIGNALING_UP+0.290
- DNA_REPAIR+0.270
- ALLOGRAFT_REJECTION+0.250
- BILE_ACID_METABOLISM+0.250
Top 10 suppressed
- G2M_CHECKPOINT-0.550
- E2F_TARGETS-0.480
- MITOTIC_SPINDLE-0.430
- PI3K_AKT_MTOR_SIGNALING-0.230
- IL6_JAK_STAT3_SIGNALING-0.210
- WNT_BETA_CATENIN_SIGNALING-0.200
- MYOGENESIS-0.160
- KRAS_SIGNALING_DN-0.150
- SPERMATOGENESIS-0.130
- APICAL_JUNCTION-0.120
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | DRR168579 | — | — | 0.817 |
| 2 | 4bafe83e-072c-4042-bd3d-5f108391ed89 | — | — | 0.789 |
| 3 | TCGA-E9-A227-01A-11R-A157-07 | — | A | 0.750 |
| 4 | SRR6013485 | — | cohortA4 | 0.747 |
| 5 | SRR8518337 | — | F | 0.745 |
| 6 | TCGA-49-4488-01A-01R-1755-07 | — | cohortA1 | 0.735 |
| 7 | SRR15030845 | — | — | 0.727 |
| 8 | TCGA-BH-A0HO-01A-11R-A034-07 | — | B | 0.723 |
| 9 | 131a9973-dfc9-4897-8c19-d5c43cecba0a | — | — | 0.720 |
| 10 | SRR4195672 | — | — | 0.720 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 32 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.580 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.430 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.400 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.330 | Inavolisib | — uncovered |
| PEROXISOME | 0.320 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.320 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.290 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.270 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.250 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.250 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.230 | Inavolisib | — uncovered |
| APOPTOSIS | 0.220 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.190 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.180 | Idelalisib | — uncovered |
| COAGULATION | 0.170 | Binimetinib | — uncovered |
| P53_PATHWAY | 0.160 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.150 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.150 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.140 | Inavolisib | — uncovered |
| COMPLEMENT | 0.140 | Inavolisib | — uncovered |